Andres Poveda, MD, on Ovarian Cancer: Assessing Maintenance Olaparib

June 09, 2020 By The ASCO Post Staff

Andres Poveda, MD, of Initia Oncology, discusses phase III results from the SOLO2 trial, which showed that, compared with placebo, maintenance olaparib improved median overall survival by 12.9 months in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation (Abstract 6002).

Related Content